Company Monitoring Page for Bluebird-Bio

latest headlines for company on cafepharma

Go or no go? The FDA’s Amylyx dilemma
EP Vantage
Tue, 05/31/22 - 10:29 am
Tags:
FDA, Amylyx, AMX0035, ALS, COVID-19, vaccines, Novavax, Moderna Therapeutics, Pfizer, Acadia Pharma, Bluebird Bio
Roche and bluebird bio settle year-long trademark case, but keep quiet on the details
Endpoints
Thu, 05/19/22 - 08:59 pm
Tags:
Bluebird Bio, Roche, Spark Therapeutics, trademark, legal
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
Pharmaforum
Thu, 04/14/22 - 10:36 am
Tags:
Bluebird Bio, ICER, beti-cel, FDA
Feeling Blue: bluebird bio cuts staff by 30%, prepares for FDA decision
BioSpace
Tue, 04/5/22 - 11:55 am
Tags:
Bluebird Bio, FDA, layoffs, restructuring, eli-cel, beti-cel
As biotech retreats, gene therapy companies retrench and redraw plans
BioPharma Dive
Thu, 03/24/22 - 08:29 pm
Tags:
biotech, gene therapy, layoffs, R&D, Bluebird Bio, Allogene, uniQure
2seventy bio's honeymoon phase is over as job cuts hit 6% of staff
Fierce Biotech
Wed, 03/23/22 - 11:10 am
Tags:
2seventy bio, layoffs, Bluebird Bio
bluebird says future uncertain as delays to gene therapies bite
Pharmaforum
Sun, 03/6/22 - 11:18 pm
Tags:
Bluebird Bio, gene therapy, beti-cel, eli-cel, lovo-cel
Court ruling on bluebird bio’s gene therapy marketing campaign 'sparks' dismay at Roche's Spark
Fierce Pharma
Thu, 01/27/22 - 10:38 am
Tags:
Bluebird Bio, gene therapy, sickle cell disease, Roche, Spark Therapeutics
No stranger to headwinds, bluebird runs into two PDUFA delays unrelated to new safety issues
Endpoints
Tue, 01/18/22 - 10:40 am
Tags:
Bluebird Bio, beti-cel, eli-cel, FDA, gene therapy, beta thalassemia
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches
Fierce Pharma
Thu, 01/13/22 - 10:32 pm
Tags:
JPMHC 2022, Bluebird Bio, gene therapy, sickle cell disease, beti-cel
JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more
Fierce Pharma
Tue, 01/11/22 - 11:37 am
Tags:
JPMHC 2022, GSK, Sanofi, Bluebird Bio
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first
Fierce Pharma
Tue, 01/11/22 - 11:31 am
Tags:
Bluebird Bio, JPMHC 2022, Pharma CEOs, Europe, Zynteglo
4 Biotechs That Were Winners at ASH
Motley Fool
Mon, 01/3/22 - 10:38 am
Tags:
ASH2021, Bristol Myers Squibb, Agios Pharmaceuticals, Forma Therapeutics, Bluebird Bio, sickle cell disease, Multiple Myeloma
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Yahoo Finance
Mon, 12/20/21 - 10:54 am
Tags:
Bluebird Bio, lovo-cel, gene therapy, sickle cell disease, FDA, clinical hold, clinical trials
ASH 2021 – Bluebird looks to revive Lentiglobin
EP Vantage
Mon, 12/13/21 - 10:34 am
Tags:
Bluebird Bio, LentiGlobin, ASH2021, sickle cell disease
Bluebird bio may finally get a gene therapy approved in the US
Endpoints
Mon, 11/22/21 - 10:28 am
Tags:
Bluebird Bio, gene therapy, FDA, Zynteglo, beta-thalassemia, priority review
With oncology spinoff done, bluebird bio moves to new digs better suited to its future
Fierce Pharma
Sun, 11/7/21 - 10:50 pm
Tags:
Bluebird Bio, oncology, Cambridge
Bluebird bio completes spinout of oncology business 2seventy bio
Bizjournals
Fri, 11/5/21 - 12:00 am
Tags:
Bluebird Bio, spinoff, oncology, 2seventy bio
Bluebird, winding down in Europe, withdraws another rare disease gene therapy
BioPharma Dive
Thu, 10/21/21 - 11:17 pm
Tags:
Bluebird Bio, gene therapy, Europe, Skysona, cerebral adrenoleukodystrophy
bluebird bio provides update on 2seventy bio spin-off
PM Live
Tue, 10/12/21 - 11:49 pm
Tags:
Bluebird Bio, 2seventy bio, spinoff, oncology

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.